MICHAEL YEBOAH: Open Payments
NPI 1285253559 · SACRAMENTO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,754 in 99 payments from 19 companies in 2025. Trend: 2023 $233 · 2024 $1,705 · 2025 $4,754
Food & beverage: $4,754
| Company | Payments | Amount |
|---|---|---|
| Gilead Sciences, Inc. | 9 | $781 |
| Amgen Inc. | 10 | $603 |
| Lilly USA, LLC | 9 | $459 |
| AstraZeneca Pharmaceuticals LP | 5 | $417 |
| ABBVIE INC. | 24 | $385 |
| Novo Nordisk Inc | 10 | $330 |
| GlaxoSmithKline, LLC. | 7 | $324 |
| Kowa Pharmaceuticals America, Inc. | 2 | $233 |
| ViiV Healthcare Company | 2 | $226 |
| Dexcom, Inc. | 6 | $212 |
Products named: REPATHA, Yeztugo, UBRELVY, Descovy, ZORYVE, NUCALA, APRETUDE, DUPIXENT.
Industry payments across CA — which companies pay providers there.
